• Novel therapies, combinations show 'increasing evidence' for role in SSc-ILD

    1 month ago - By Healio

    A number of new therapies, including immunosuppressive drugs and drug combinations, have shown efficacy in mitigating scleroderma-associated interstitial lung disease, according to a speaker at the ACR State-of-the-Art Clinical Symposium.
    Kristin B. Highland, MD, director of the Rheumatic Lung Disease Program at the Cleveland Clinic, aimed to provide a comprehensive overview of scleroderma-associated interstitial lung disease and review current data on the treatment of this patient population.
    “When I am thinking about treating patients with scleroderma ILD, I use Goh staging
    Read more ...